The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Children with cancer receive many medications outside the hospital administered by their caregivers.
The study by Walsh et al. shows the number and types of medication errors in these patients. The study includes data from three different centers.
Importantly, the study shows the types of errors that cause harm. The authors describe how the harmful errors can be prevented.
We suggest ways these...
Background
Leukemia and lymphoma (LL) are the most common cancer diagnoses of childhood with high survival rates, but not without impact on the child's functioning and quality of life. This study aimed to use patient‐reported data to describe the symptomatic adverse event (AE) experiences among children with LL diagnoses.
Methods
Two hundred and fifty seven children and adolescents aged 7–18 years...
Cutaneous lesions may represent the initial sign of various neoplasms in children, including histiocytosis, neuroblastomas, and lymphomas. Primary cutaneous lymphoblastic lymphomas are rare and involve mostly the B‐cell phenotype. Herein, we report a case of isolated, primary B‐lymphoblastic lymphoma in a 7‐month‐old infant and emphasize the importance of early diagnosis.
Background
A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies.
Methods
Patients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more...